PMGC Holdings Inc.
No enriched coverage for $ELAB in the last 7 days.
No SEC Form 4 filings for $ELAB in the last 30 days.
See all $ELAB insider activity →PMGC Holdings’ subsidiary NorthStrive Biosciences said it will start an independent flow cytometry study to quantify myostatin antigen expression on its engineered probiotic EL-22. The results are intended to support comparability with materials made by MOA Life Plus Co. Ltd. Shares rose 14.06% to $1.20, per Benzinga Pro.
NorthStrive Biosciences, a PMGC Holdings (NASDAQ: ELAB) subsidiary, plans an independent FACS flow cytometry study to quantify latent myostatin antigen expression on EL-22 engineered Lactobacillus casei made by NorthStrive. The results will be compared with EL-22 material previously manufactured by MOA Life Plus to support product identity, manufacturing consistency, and IND-enabling characterization.
PMGC Holdings Inc. (NASDAQ: ELAB) said its subsidiary NorthStrive Biosciences plans an independent FACS flow cytometry study to quantify latent myostatin antigen expression on NorthStrive-manufactured EL-22 (engineered Lactobacillus casei) and compare it with material previously made by MOA Life Plus Co. Ltd. The work aims to support product identity, manufacturing consistency, and IND-enabling characterization.
Recent ELAB coverage spans corporate actions, technology and financial news.
The independent study is a product characterization and manufacturing-consistency step that can reduce regulatory and comparability risk for EL-22.
Adds incremental regulatory-grade product characterization work for EL-22, but no new clinical or financial datapoint is provided.
Adds incremental, regulatory-facing analytical work for EL-22, but provides no results, timeline certainty, or new clinical/regulatory milestone.
The disclosed subsidiary consolidation is a corporate-structure change, but the article provides no stated strategic rationale, limiting fundamental read-through.
This is a corporate-structure change within PMGC’s wholly owned subsidiaries, with limited direct read-through to consolidated earnings but potential integration and legal/operational impacts.
alphai scores every news story that mentions ELAB with an AI model for sentiment and relevance, and aggregates insider trades from PMGC Holdings Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
PMGC Holdings’ subsidiary NorthStrive Biosciences said it will start an independent flow cytometry study to quantify myostatin antigen expression on its engineered probiotic EL-22. The results are intended to support comparability with materials made by MOA Life Plus Co. Ltd. Shares rose 14.06% to $1.20, per Benzinga Pro.
2 min readNorthStrive Biosciences, a PMGC Holdings (NASDAQ: ELAB) subsidiary, plans an independent FACS flow cytometry study to quantify latent myostatin antigen expression on EL-22 engineered Lactobacillus casei made by NorthStrive. The results will be compared with EL-22 material previously manufactured by MOA Life Plus to support product identity, manufacturing consistency, and IND-enabling characterization.
2 min readPMGC Holdings Inc. (NASDAQ: ELAB) said its subsidiary NorthStrive Biosciences plans an independent FACS flow cytometry study to quantify latent myostatin antigen expression on NorthStrive-manufactured EL-22 (engineered Lactobacillus casei) and compare it with material previously made by MOA Life Plus Co. Ltd. The work aims to support product identity, manufacturing consistency, and IND-enabling characterization.
3 min readPMGC Holdings’ NASDAQ-listed ELAB rose more than 37% after an SEC filing said AGA Precision Systems LLC will merge into A&B Aerospace Inc., with A&B as the surviving entity. AGA membership interests will be canceled without consideration, while A&B shares remain unchanged. The filing dated Jul. 2 was signed by CEO Graydon Bensler. ELAB closed at $1.06.
4 min readPMGC Holdings Inc. (ELAB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001840563 0001840563 2026-07-02 2026-07-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Repor
2 min readPMGC Holdings Inc. (ELAB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ea029727201ex10-1.htm STANDARD EXCLUSIVE LICENSE AGREEMENT WITH KNOW-HOW BETWEEN NORTHSTRIVE DEFENSE TECH LLC AND LICENSOR Exhibit 10.1 PORTIONS OF THIS EXHIBIT HAVE BEEN REDACTED BECAUSE IT IS NOT MATERIAL AND OF A TYPE THAT PMGC HOLDINGS INC. TREATS AS PRIVATE OR CONF
5 min readEgypt’s government offerings programme has temporarily listed four state-owned firms on the Egyptian Exchange: ENPPI, ELAB, PMS, and El Maamora for Construction & Touristic Development. The initiative is intended to improve disclosure, transparency, and investor confidence ahead of future public offerings; it targets 10 petroleum firms, with 3 completed and 20 of 30 firms overall in temporary listings.
3 min readPMGC Holdings Inc. (ELAB) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false --12-31 0001840563 0001840563 2026-06-05 2026-06-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date
3 min readPMGC Holdings Inc. said it entered a non-binding letter of intent to acquire a 76% controlling interest in a privately held precision machining and contract manufacturing company based in Arizona, according to the company. The target was not named. Based on unaudited figures provided to PMGC, the company generated about $5.46 million in FY2025 revenue and about $1.05 million in EBITDA.
3 min readPMGC Holdings has acquired A&B Aerospace, a precision-machining and aerospace-manufacturing company, as part of its strategy to build a U.S.-based precision manufacturing platform. This marks PMGC's fifth acquisition in the past year, aligning with favorable market conditions in the aerospace and defense sectors. A&B Aerospace generated approximately $5.0 million in revenue and $610,000 in adjusted EBITDA for the trailing twelve-month period ended February 28, 2026.
3 min read
